.css-1gu7o1h p{color:#FFFFFF;font-weight:600;font-size:1rem;}.css-1gu7o1h .typo{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;}.css-1hgicv7{box-sizing:border-box;-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;}.css-1hgicv7 p{color:#FFFFFF;font-weight:600;font-size:1rem;}.css-1hgicv7 .typo{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;}

JavaScript is currently disabled in your browser. For the best experience, please enable JavaScript to enjoy full website functionality. Thank you!

Steps to Enable JavaScript

A Study of Vedolizumab in Adults in Real-World Practice

clipboard-pencil

About the study

Vedolizumab is a medicine that is currently prescribed for adults with moderately to severely active ulcerative colitis or Crohn's disease. In this study, adults with ulcerative colitis or Crohn's disease will be treated with vedolizumab according to their clinic's standard practice. The main aim of the study is to check if participants have side effects from vedolizumab. The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study.

user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

Diagnosed with UC or CD
Firstly prescribed with vedolizumab

EXCLUSION CRITERIA

Exclusion Criteria:

Currently enrolled in or plan to participate in any other clinical trials (that is, interventional study)
Contraindicated for vedolizumab according to product package insert

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Call +1-877-825-3327

Email Study Center

Study’s details

Contition

Colitis, Ulcerative,Crohn Disease

Age (in years)

18+

Participants needed

750

Est. Completion Date

May 31, 2024

Treatment type

Observational

Sponsor

Takeda

ClinicalTrials.gov identifier

NCT04872491

Study number

vedolizumab-5064

Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?